tradingkey.logo
tradingkey.logo
Search

ProKidney Corp

PROK
Add to Watchlist
2.030USD
+0.140+7.41%
Close 07/02, 13:00ETQuotes delayed by 15 min
288.22MMarket Cap
LossP/E TTM

TradingKey Stock Score of ProKidney Corp

Currency: USD Updated: 2026-07-02

Key Insights

ProKidney Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ProKidney Corp's Score

Industry at a Glance

Industry Ranking
120 / 387
Overall Ranking
244 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

ProKidney Corp Highlights

StrengthsRisks
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Growing
The company is in a growing phase, with the latest annual income totaling USD 893.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 893.00K.
Fairly Valued
The company’s latest PE is -3.86, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.49M shares, increasing 8.56% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 1.31K shares of this stock.

Analyst Rating

Based on 9 analysts
Buy
Current Rating
7.417
Target Price
+292.42%
Upside Space

FAQs

How does TradingKey generate the Stock Score of ProKidney Corp?

The TradingKey Stock Score provides a comprehensive assessment of ProKidney Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of ProKidney Corp’s performance and outlook.

How do we generate the financial health score of ProKidney Corp?

To generate the financial health score of ProKidney Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects ProKidney Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of ProKidney Corp.

How do we generate the company valuation score of ProKidney Corp?

To generate the company valuation score of ProKidney Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare ProKidney Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of ProKidney Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of ProKidney Corp.

How do we generate the earnings forecast score of ProKidney Corp?

To calculate the earnings forecast score of ProKidney Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on ProKidney Corp’s future.

How do we generate the price momentum score of ProKidney Corp?

When generating the price momentum score for ProKidney Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of ProKidney Corp’s prices. A higher score indicates a more stable short-term price trend for ProKidney Corp.

How do we generate the institutional confidence score of ProKidney Corp?

To generate the institutional confidence score of ProKidney Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about ProKidney Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of ProKidney Corp.

How do we generate the risk management score of ProKidney Corp?

To assess the risk management score of ProKidney Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of ProKidney Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of ProKidney Corp.